Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.31 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.31 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.30 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27734241 | 1.00 | CDK5 (0.36) | CDK5CDK5R1HRH3POLBTSHR | |
| SCHEMBL29844508 | 0.98 | CDK5 (0.37) | CDK5CDK5R1HRH3POLBTSHR | |
| SCHEMBL275596 | 0.98 | CDK5 (0.37) | CDK5CDK5R1HRH3POLBTSHR | |
| SCHEMBL29844446 | 0.98 | CDK5 (0.37) | CDK5CDK5R1HRH3POLBTSHR | |
| SCHEMBL29844647 | 0.89 | HTR2A (0.47) | CDK5CDK5R1HRH3POLBTSHR | |
| SCHEMBL1230997 | 0.89 | HTR2A (0.47) | CDK5CDK5R1HRH3POLBTSHR | |
| SCHEMBL14327287 | 0.87 | ALDH1A1 (0.36) | CDK5CDK5R1HRH3TSHRGAA | |
| SCHEMBL12009751 | 0.83 | — | — | |
| SCHEMBL19682135 | 0.77 | GAA (0.34) | HRH3POLBGAAALDH1A1RAB9A | |
| SCHEMBL12336639 | 0.77 | ESR1 (0.37) | CDK5CDK5R1POLBTSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143201-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS (US) | 2022-05-12 | — | — | US | disclosed |
| US-11266742-B2 | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates | NEKTAR THERAPEUTICS (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200276320-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS (US) | 2020-09-03 | — | — | US | disclosed |
| US-10695435-B2 | Composition comprising a polymeric reagent | NEKTAR THERAPEUTICS (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190046651-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-10130720-B2 | Composition comprising a polymeric reagent | NEKTAR THERAPEUTICS (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170348426-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2017-12-07 | — | — | US | disclosed |
| US-9775911-B2 | Composition comprising a polymeric reagent | NEKTAR THERAPEUTICS (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160324973-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2016-11-10 | — | — | US | disclosed |
| US-9381254-B2 | Methods for preparing polymeric reagents | NEKTAR THERAPEUTICS (US) | 2016-07-05 | — | — | US | disclosed |
| US-8252275-B2 | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates | NEKTAR THERAPEUTICS (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1968644-B1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2364735-A2 | Branched PEG conjugates of GLP-1 | Nektar Therapeutics (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2279758-A2 | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates | Nektar Therapeutics (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| EP-1968644-A2 | POLYMER CONJUGATES OF GLP-1 | Nektar Therapeutics Al, Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1896082-A2 | CONJUGATES HAVING A DEGRADABLE LINKAGE AND POLYMERIC REAGENTS USEFUL IN PREPARING SUCH CONJUGATES | Nektar Therapeutics AL, Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007075534-A2 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2006138572-A2 | CONJUGATES HAVING A DEGRADABLE LINKAGE AND POLYMERIC REAGENTS USEFUL IN PREPARING SUCH CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293499-A1 | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates | NEKTAR THERAPEUTICS | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324973-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CAT, LPO, GPX4 | HRH3 2287/4885GLA 799/4885GAA 1093/4885 |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | HRH3 3532/4885GLA 794/4885GAA 1045/4885 |
| US-20220143201-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CD44, FCGRT, C9 | HRH3 123/4885GLA 1320/4885GAA 613/4885 |
| US-20200276320-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CD44, FCGRT, C9 | HRH3 123/4885GLA 1320/4885GAA 613/4885 |
| US-10130720-B2 | Composition comprising a polymeric reagent | CD44, FCGRT, C9 | HRH3 123/4885GLA 1320/4885GAA 613/4885 |
| US-11266742-B2 | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates | CD44, DNPEP, SI | HRH3 260/4885GLA 557/4885GAA 188/4885 |
| US-20190046651-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CD44, FCGRT, C9 | HRH3 123/4885GLA 1320/4885GAA 613/4885 |
| US-20170348426-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CD44, FCGRT, C9 | HRH3 123/4885GLA 1320/4885GAA 613/4885 |
| US-10695435-B2 | Composition comprising a polymeric reagent | CD44, FCGRT, C9 | HRH3 123/4885GLA 1320/4885GAA 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.